Hae Yoon Choi1, Sungeun Kim, Ji Woo Park, Nam Seok Lee, Soon Young Hwang, Joo Young Huh, Ho Cheol Hong, Hye Jin Yoo, Sei Hyun Baik, Byung-Soo Youn, Christos S Mantzoros, Kyung Mook Choi. 1. Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine (H.Y.C., H.C.H., H.J.Y., S.Y.B., K.M.C.), Korea University, Seoul 136-701, Korea; Department of Nuclear Medicine, College of Medicine (S.K.), Korea University, Seoul 136-701, Korea; AdipoGen, Inc (J.W.P., N.S.L., B.-S.Y.), Incheon 406-840, Korea; Department of Biostatistics, College of Medicine (S.W.H.), Korea University, Seoul 136-701, Korea; and Section of Endocrinology (J.Y.H., C.S.M.), VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts 02130.
Abstract
CONTEXT: Irisin is an exercise-induced novel myokine that drives brown-fat-like conversion of white adipose tissue and has been suggested to be a promising target for the treatment of obesity-related metabolic disorders. OBJECTIVE: To assess the association of circulating irisin concentrations with brown adipose tissue (BAT) and/or sarcopenia in humans. SETTING AND DESIGN: We examined irisin levels in 40 BAT-positive and 40 BAT-negative women detected by (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET). In a separate study, we also examined 401 subjects with or without sarcopenia defined by skeletal muscle mass index (SMMI) and appendicular skeletal muscle (ASM)/height(2) using dual-energy x-ray absorptiometry. RESULTS: Among 6877 consecutive (18)FDG-PET scans in 4736 subjects, 146 subjects (3.1%) had positive BAT scans. The BAT-detectable group and the matched BAT-undetectable group did not differ in circulating irisin levels measured using two different ELISA kits (P = .747 and P = .160, respectively). Serum irisin levels were not different between individuals with sarcopenia and those without sarcopenia using either kit (P = .305 and P = .569, respectively). Also, serum irisin levels were not different between groups defined by ASM/height(2) using either kit (P = .352 and P = .134, respectively). Although visceral fat area and skeletal muscle mass showed significant difference according to tertiles of SMMI levels, irisin concentrations did not differ. CONCLUSIONS: Circulating irisin levels were not different in individuals with detectable BAT or those with sarcopenia compared with control subjects and were not correlated with SMMI.
CONTEXT: Irisin is an exercise-induced novel myokine that drives brown-fat-like conversion of white adipose tissue and has been suggested to be a promising target for the treatment of obesity-related metabolic disorders. OBJECTIVE: To assess the association of circulating irisin concentrations with brown adipose tissue (BAT) and/or sarcopenia in humans. SETTING AND DESIGN: We examined irisin levels in 40 BAT-positive and 40 BAT-negative women detected by (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET). In a separate study, we also examined 401 subjects with or without sarcopenia defined by skeletal muscle mass index (SMMI) and appendicular skeletal muscle (ASM)/height(2) using dual-energy x-ray absorptiometry. RESULTS: Among 6877 consecutive (18)FDG-PET scans in 4736 subjects, 146 subjects (3.1%) had positive BAT scans. The BAT-detectable group and the matched BAT-undetectable group did not differ in circulating irisin levels measured using two different ELISA kits (P = .747 and P = .160, respectively). Serum irisin levels were not different between individuals with sarcopenia and those without sarcopenia using either kit (P = .305 and P = .569, respectively). Also, serum irisin levels were not different between groups defined by ASM/height(2) using either kit (P = .352 and P = .134, respectively). Although visceral fat area and skeletal muscle mass showed significant difference according to tertiles of SMMI levels, irisin concentrations did not differ. CONCLUSIONS: Circulating irisin levels were not different in individuals with detectable BAT or those with sarcopenia compared with control subjects and were not correlated with SMMI.
Authors: T Ebert; S Kralisch; U Wurst; M Scholz; M Stumvoll; P Kovacs; M Fasshauer; A Tönjes Journal: Int J Obes (Lond) Date: 2015-08-19 Impact factor: 5.095
Authors: A Rodríguez; S Becerril; L Méndez-Giménez; B Ramírez; N Sáinz; V Catalán; J Gómez-Ambrosi; G Frühbeck Journal: Int J Obes (Lond) Date: 2014-09-09 Impact factor: 5.095
Authors: Laurent Maïmoun; Denis Mariano-Goulart; Helena Huguet; Eric Renard; Patrick Lefebvre; Marie-Christine Picot; Anne-Marie Dupuy; Jean-Paul Cristol; Philippe Courtet; Vincent Boudousq; Antoine Avignon; Sébastien Guillaume; Ariane Sultan Journal: Endocr Connect Date: 2022-05-10 Impact factor: 3.221